Stock comparison
Cardinal Health
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CAH
Cardinal Health
Market cap
$47B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CAH | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 40D | 72B | RMD |
| Benjamin Graham | 38D | 75B | RMD |
| Philip Fisher | 46D | 75B | RMD |
| Peter Lynch | 52C | 58C | RMD |
| Joel Greenblatt | 42D | 47D | RMD |
| Charlie Munger | 33F | 69B | RMD |
| Terry Smith | 39D | 73B | RMD |
Side-by-side metrics
| Metric | CAH | RMD |
|---|---|---|
| Market cap | $47B | $30.18B |
| P/E (TTM) | 29.5x | 19.6x |
| EV/EBIT | 22.4x | 17.1x |
| ROIC (TTM) | 11.62% | 19.63% |
| Gross margin | 3.68% | 61.69% |
| Net margin | 0.62% | 27.44% |
| Revenue CAGR 5y | 8.19% | 12.64% |
| EPS CAGR 5y | 32.7% | 30.73% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 1.04% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CAH leads on
- Debt / Equity-vs 0.1x+104%
- Market cap$47Bvs $30.18B+36%
- EPS CAGR 5y32.7%vs 30.73%+6%
RMD leads on
- Net margin27.44%vs 0.62%+98%
- Gross margin61.69%vs 3.68%+94%
- ROIC (TTM)19.63%vs 11.62%+41%
- Revenue CAGR 5y12.64%vs 8.19%+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.